Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 372,895
  • Shares Outstanding, K 45,923
  • Annual Sales, $ 57,490 K
  • Annual Income, $ -102,240 K
  • 60-Month Beta 0.70
  • Price/Sales 6.44
  • Price/Cash Flow N/A
  • Price/Book 5.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.34
  • Number of Estimates 5
  • High Estimate 1.64
  • Low Estimate -0.51
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +153.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.78 +4.10%
on 06/02/20
15.44 -47.54%
on 05/13/20
-3.11 (-27.74%)
since 05/01/20
3-Month
3.60 +125.31%
on 03/16/20
15.44 -47.54%
on 05/13/20
+0.80 (+10.96%)
since 03/03/20
52-Week
3.60 +125.31%
on 03/16/20
15.44 -47.54%
on 05/13/20
-2.00 (-19.80%)
since 06/03/19

Most Recent Stories

More News
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GSX, GRPN and CTMX

NEW YORK, NY / ACCESSWIRE / June 2, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders...

GSX : 38.92 (+5.27%)
GRPN : 1.2800 (+3.23%)
CTMX : 8.14 (+0.25%)
CTMX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2020 in the Class Action Filed on Behalf of CytomX Therapeutics, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - June 1, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc. (NASDAQ: CTMX) alleging...

CTMX : 8.14 (+0.25%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytomX Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2020 - CTMX

New York, New York--(Newsfile Corp. - June 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

CTMX : 8.14 (+0.25%)
Cytomx Therapeut Falls 7.05% on Heavy Volume: Watch For Potential Rebound

Cytomx Therapeut (NASDAQ:CTMX) traded in a range yesterday that spanned from a low of $8.02 to a high of $8.74. Yesterday, the shares fell 7.1%, which took the trading range below the 3-day low of $8.51...

CTMX : 8.14 (+0.25%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LBRT, ZM and CTMX

NEW YORK, NY / ACCESSWIRE / June 1, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders...

BDFC : N/A (unch)
LBRT : 5.75 (+1.59%)
ZM : 218.66 (+5.08%)
CTMX : 8.14 (+0.25%)
CytomX Therapeutics Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - June 1, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. ("CytomX" or the "Company") (NASDAQ:...

CTMX : 8.14 (+0.25%)
ROSEN, A RESPECTED AND LEADING FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important July 20 Deadline in Securities Class Action - CTMX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May 13, 2020, inclusive (the "Class Period")...

CTMX : 8.14 (+0.25%)
Is CytomX Therapeutics (CTMX) Stock a Solid Choice Right Now?

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CTMX : 8.14 (+0.25%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BBBY, GRPN and CTMX

NEW YORK, NY / ACCESSWIRE / June 1, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...

BBBY : 7.76 (+2.78%)
GRPN : 1.2800 (+3.23%)
CTMX : 8.14 (+0.25%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytomX Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2020 - CTMX

New York, New York--(Newsfile Corp. - May 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

CTMX : 8.14 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 8.43
1st Resistance Point 8.27
Last Price 8.14
1st Support Level 7.87
2nd Support Level 7.63

See More

52-Week High 15.44
Fibonacci 61.8% 10.92
Fibonacci 50% 9.52
Last Price 8.14
Fibonacci 38.2% 8.12
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar